Poniard plunges after picoplatin fails pivotal lung cancer trial
This article was originally published in Scrip
Executive Summary
Poniard Pharmaceuticals' only drug candidate in clinical development, the chemotherapeutic agent picoplatin, has failed to improve overall survival in its pivotal Phase III SPEAR trial in the second-line treatment of small cell lung cancer (SCLC), leading its shares to plunge by over 75% on Nasdaq on November 17th.